American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgery
Surgery for Obesity and Related Diseases · 2026-07 · 22 (7) · 699-706
DOI: 10.1016/j.soard.2026.04.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Surgery for Obesity and Related Diseases, 2026-07. Verfasst von R Wesley Vosburg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, HCA Grand Strand Medical Center, Myrtle Beach, South Carolina. Electronic address: wesvosburg@gmail.com. Hauptthemen laut MEDLINE: Bariatric Surgery, Obesity, Morbid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity, producing durable weight loss and improvement in obesity-related comorbidities. However, a subset of patients experience inadequate weight loss (non-response, NR) or weight recurrence (WR), which can lead to persistence or recurrence of metabolic disease, diminished quality of life, and warrants for further treatment interventions. OBJECTIVES This review summarizes current treatment options for NR and WR after MBS, including surgical revisions, endoscopic therapies, and obesity modifying medications (OMMs). METHODS A comprehensive literature review was performed, incorporating recent systematic reviews, meta-analyses, and retrospective series evaluating outcomes of revisional procedures, endoscopic approaches, and pharmacotherapy for patients with NR and WR following MBS. RESULTS Revisional surgical options after Roux-en-Y gastric bypass (RYGB) include pouch revision, banding, distalization, and conversion to biliopancreatic diversion-duodenal switch or single anastomosis duodeno-ileostomy with sleeve gastrectomy (SADI-S). After sleeve gastrectomy, revisional strategies include re-sleeve, conversion to RYGB, SADI-S, or one-anastomosis gastric bypass. Endoscopic therapies such as transoral outlet reduction and argon plasma coagulation offer modest but clinically meaningful weight loss with low complication rates. OMMs, particularly glucagon-like peptide-1 (GLP-1) receptor agonists (semaglutide) and dual gastrointestinal peptide/GLP-1 receptor agonists (tirzepatide), have demonstrated weight loss in post-MBS patients. Across all modalities, variability in outcomes and high loss to follow-up limit data quality. CONCLUSIONS NR and WR after MBS require individualized, multidisciplinary management on a case-by-case basis. Surgical, endoscopic, and pharmacologic options all play important roles, and emerging OMMs represent a major advance. Standardized outcome reporting and prospective studies are needed to refine treatment algorithms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, HCA Grand Strand Medical Center, Myrtle Beach, South Carolina. Electronic address: wesvosburg@gmail.com.
- Department of Surgery, UCSF, San Francisco, California.
- Department of Surgery, Stanford University School of Medicine, Stanford, California.
- Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
- Department of Surgery, Vanderbilt Medical Center, Nashville, Tennessee.
- Department of Surgery, Stanford University School of Medicine, Palo Alto, California.
Zitieren
APA
Vosburg, R. W., Carter, J., Azagury, D., Nimeri, A., Northup, C. J., Eisenberg, D., Rogers, A. M., & Papasavas, P. (2026). American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgery. Surgery for Obesity and Related Diseases, 22(7), 699-706. https://doi.org/10.1016/j.soard.2026.04.002
Vancouver
Vosburg RW, Carter J, Azagury D, Nimeri A, Northup CJ, Eisenberg D, et al. American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgery. Surgery for Obesity and Related Diseases. 2026;22(7):699-706. doi:10.1016/j.soard.2026.04.002
BibTeX
@article{Vosburg2026,
author = {Vosburg, R Wesley and Carter, Jonathan and Azagury, Dan and Nimeri, Abdelrahman and Northup, C Joe and Eisenberg, Daniel and Rogers, Ann M and Papasavas, Pavlos},
title = {American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgery},
journal = {Surgery for Obesity and Related Diseases},
year = {2026},
volume = {22},
number = {7},
pages = {699--706},
doi = {10.1016/j.soard.2026.04.002}
}
EUVIMED